Calliditas Signs a License Agreement with STADA to Commercialize Specialty Therapy for the Treatment of IgA Nephropathy in EU

 Calliditas Signs a License Agreement with STADA to Commercialize Specialty Therapy for the Treatment of IgA Nephropathy in EU

Shots:

  • Calliditas to receive $24M upfront and is eligible to receive ~$91M as regulatory and commercialization milestones along with royalties on net sales
  • The companies collaborated to develop a new oral formulation that downregulates IgA1 by combining Calliditas’ drug-delivery expertise with STADA’s extensive marketing and sales platform for specialty and nephrology therapies
  • The companies collaborated to bring a specialty therapy for IgAN in EU market, If approved, the therapy would be available to EU patients in H1’22 & would be the first approved treatment in the EU for chronic autoimmune kidney disease IgAN

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Pharmaceutical Technology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post